Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy.

The Lancet. Oncology·2026

Same author

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Blood cancer journal·2026

Same author

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Blood cancer journal·2025

Same author

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.

The Lancet. Oncology·2025

Same author

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.

Blood advances·2025

Same author

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.

The New England journal of medicine·2024

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Current treatment approaches for diffuse large B-cell lymphoma.

Tim Illidge¹, Shaun Tolan

¹School of Cancer Imaging Sciences, CR UK Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK. tmi@manchester.ac.uk

Leukemia & Lymphoma

|April 10, 2008

Summary

This summary is machine-generated.

Recent advancements in diffuse large B-cell lymphoma (DLBCL) treatment, including dose-intense chemotherapy and rituximab, have improved patient outcomes. Further research is needed for high-risk DLBCL, focusing on genetic factors and radiotherapy

Related Experiment Videos

Last Updated: Jul 6, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

Hematology
Oncology
Clinical Research

Background:

Diffuse large B-cell lymphoma (DLBCL) is a significant hematologic malignancy.
Treatment advancements have improved patient survival over the past decade.

Purpose of the Study:

To review recent developments in DLBCL treatment.
To assess the impact of dose-dense/intense chemotherapy and rituximab on patient outcomes.
To explore future strategies for high-risk DLBCL and the role of radiotherapy.

Main Methods:

Review of clinical data and treatment strategies for DLBCL.
Analysis of outcomes associated with dose-dense/intense chemotherapy and rituximab.
Evaluation of current evidence for radiotherapy in DLBCL management.

Main Results:

Dose-dense/intense chemotherapy and rituximab have led to higher response rates, lower relapse rates, and improved event-free survival (EFS) and overall survival (OS).
These strategies show particular benefit in patients with better prognostic indicators.
High-risk DLBCL remains a challenge, necessitating novel treatment approaches.

Conclusions:

Current treatment strategies have significantly improved DLBCL outcomes.
Understanding genetic factors and chemotherapy resistance is crucial for advancing treatment.
The role of radiotherapy in DLBCL management requires further rigorous evaluation.